Your browser doesn't support javascript.
loading
Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7.
Grattan, Vincent; Vaino, Andrew R; Prensky, Zachary; Hixon, Mark S.
Affiliation
  • Grattan V; LB Pharmaceuticals Inc., 575 Madison Avenue, New York, New York 10022, United States.
  • Vaino AR; LB Pharmaceuticals Inc., 575 Madison Avenue, New York, New York 10022, United States.
  • Prensky Z; LB Pharmaceuticals Inc., 575 Madison Avenue, New York, New York 10022, United States.
  • Hixon MS; Mark S. Hixon Consulting LLC, 11273 Spitfire Road, San Diego, California 92126, United States.
ACS Omega ; 4(9): 14151-14154, 2019 Aug 27.
Article in En | MEDLINE | ID: mdl-31497735
ABSTRACT
Benzamide antipsychotics such as amisulpride are dosed as racemates though efficacy is assumed to be mediated through S enantiomer binding to D2 receptors. At prescribed doses, the benzamides likely display polypharmacy since brain exposure should be sufficient to engage the 5-HT7 receptors, as well. Curiously, the studies herein reveal that racemic dosing is required to engage both targets since the D2 receptor has an almost 40-fold selectivity for the S enantiomer, while the 5-HT7 receptor has greater than 50-fold preference for the R enantiomer.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Omega Year: 2019 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Omega Year: 2019 Document type: Article Affiliation country: United States
...